Key Takeaways: A 2026 prospective study of 395 older Australian women from the ASPREE cohort found that a three-year decline in natural blood testosterone did not predict any decline in global cognition, memory, verbal fluency, or processing speed. About 39% of the women had measurably lower testosterone over the follow-up, yet their cognitive trajectories were no different. A subgroup limited to women aged 70 to 79 showed the same null result. The takeaway is narrow but important: the natural fall in testosterone that happens with age does not appear to be a cause of cognitive decline in women. This does not mean testosterone therapy is useless for cognitive symptoms -- that is a separate question the study did not test -- but it does undercut the common marketing claim that "low testosterone is causing your brain fog." For midlife women with cognitive symptoms, the more likely drivers are estradiol changes, sleep disruption, thyroid disease, iron deficiency, and mood -- which is why a real workup matters more than a single hormone number.
What the Study Found
A 2026 prospective cohort study published in Climacteric, the journal of the International Menopause Society, asked a direct question: does declining natural testosterone contribute to cognitive decline in older women? [1]
The researchers followed 395 community-dwelling older Australian women drawn from the ASPREE trial (a large aspirin-in-the-elderly study, median age around 78). They measured serum testosterone at baseline and again three years later, and administered a comprehensive cognitive test battery at both timepoints -- covering global cognition, immediate and delayed memory recall, verbal fluency, and processing speed.
About 39% of the women showed a measurable drop in testosterone across the three years. The central finding: that decline was not associated with any deterioration in cognitive performance. Not global cognition. Not memory. Not fluency. Not processing speed.
When the researchers restricted the analysis to women aged 70 to 79 -- a tighter age band -- the null result held. A fall in natural testosterone across three years simply did not move the needle on cognition in this population.
The authors' conclusion is appropriately bounded: natural variation in testosterone at the low late-life levels typical of older women does not appear to influence cognitive trajectories over a three-year window.
Why This Matters: The Brain-Fog Marketing Claim
If you have searched for help with brain fog, memory slips, or mental clarity in your 40s, 50s, or beyond, you have probably encountered a confident claim: low testosterone is the cause, and testosterone will fix it. It shows up in clinic marketing, influencer content, and supplement ads aimed at women.
This study is a useful corrective. It is the kind of data that should make you skeptical of any clinic or influencer who tells you your cognitive symptoms are simply low testosterone. The natural decline in testosterone -- the thing that happens to essentially every woman with age -- is not what is driving cognitive change.
That distinction matters because the wrong explanation leads to the wrong workup. If a woman is told her brain fog is "just low T," she may start testosterone, feel no cognitive benefit, and never get evaluated for the things that actually cause midlife cognitive symptoms. A real evaluation looks wider. See HRT and Brain Fog for the full framework.
What Actually Drives Cognitive Symptoms in Midlife Women
If natural testosterone decline is not the cause, what is? Usually a combination of these:
- Estradiol changes. The dominant hormonal driver of cognitive symptoms in the menopause transition is the fluctuation and decline of estrogen, not testosterone. Estradiol has well-documented effects on verbal memory and processing speed, and many women notice word-finding difficulty and concentration problems track with their perimenopausal estrogen swings. This is why the grey matter and brain imaging research in menopause focuses on estrogen.
- Sleep disruption. Hot flashes, night sweats, and perimenopausal insomnia fragment sleep, and fragmented sleep alone produces measurable cognitive impairment. Fix the sleep and the "brain fog" often lifts.
- Thyroid disease. Hypothyroidism is common in midlife women and classically presents with mental sluggishness, poor concentration, and fatigue. It is easy to test and easy to miss.
- Iron deficiency. Low ferritin -- common in women who still menstruate or who recently transitioned -- causes fatigue and cognitive cloudiness independent of anemia.
- Depression and anxiety. Mood disorders impair concentration and memory directly. The cognitive symptoms of depression are frequently mistaken for a hormone problem.
- Chronic stress and medications. Cortisol load and the side effects of common medications (antihistamines, some blood pressure agents, sleep aids) both blunt cognition.
The clinical point: cognitive symptoms in midlife women deserve a differential diagnosis, not a single-hormone explanation. A clinic that reflexively attributes everything to low testosterone is skipping the workup that would actually help you.
The Nuance: Decline Versus Treatment Are Different Questions
It is worth being precise about what this study does and does not say, because the distinction is easy to blur.
What it says: a natural, gradual fall in testosterone over three years does not cause cognitive decline in older women.
What it does not say: that giving testosterone therapy to a symptomatic woman with low levels will not help her.
These are genuinely different questions. The first is about whether endogenous decline is a cause of cognitive aging. The second is about whether a treatment improves symptoms in people who have them. A study can answer the first cleanly and say nothing about the second.
On the treatment question, the evidence is thinner and more mixed. A 332-woman real-world cohort on individualized testosterone therapy reported cognitive gains emerging at four to six months, alongside earlier energy and mood improvement -- but that data is observational and cannot separate testosterone effect from placebo. Older pilot studies of testosterone in postmenopausal women showed modest verbal-memory improvements. The international consensus position statement on testosterone for women restricts the recommended indication to hypoactive sexual desire disorder, precisely because that is the only area with adequate randomized trial support; cognition is not yet on that list.
